Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Dementia Australia awards $385,000 to support dementia-friendly projects

Dementia Australia 2 mins read

Dementia Australia has awarded more than $385,000 in grants to support 27 communities across Australia to become more dementia-friendly.

Each of the 27 community groups were awarded up to $15,000 to fund dementia-friendly initiatives tailored to the issues and opportunities in their area.

Dementia Australia Executive Director Services, Advocacy & Research Dr Kaele Stokes said one of the keys to the success of such initiatives was that grant recipients would work closely with local people living with dementia.

“We know that discrimination and social isolation have a big impact on people living with dementia,” Dr Stokes said.

“With more than 421,000 Australians living with dementia, and an estimated two-thirds of those living in the community, it is vital that people living with dementia are included in discussions about what support they need to continue to participate in their communities.

“Dementia-friendly communities play a critical role in encouraging inclusivity, respecting the rights of people with dementia and facilitating access to the services, supports, activities and spaces to which every Australian is entitled. Projects like these allow people living with dementia to meaningfully and purposefully contribute to their community.”

This year’s Community Engagement Program grant round was the largest ever pool of funding with grants supporting community associations, businesses, organisations and groups to develop dementia-friendly projects that reflected community need.

Five grant rounds have been delivered so far, with funds totalling more than $1.1 million delivered to more than 90 groups.

The 2024 grant round prioritised projects that meaningfully consulted and collaborated with people impacted by dementia in their design and delivery, brought together collaborative local partnerships and met the needs of diverse communities.

A full list of the community groups awarded a grant can be found on our website.

This Dementia Australia initiative received funding from the Australian Government.

-Ends-

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Leisa Hurst, Senior Media and Communications Advisor, 0487 763 459 [email protected]

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 13/05/2025
  • 12:10
EnGeneIC

EnGeneIC launches groundbreaking new Australian trial for innovative cancer therapy, with international trial site in Singapore to follow

First Patient dosed in Phase I/IIa Basket Trial for Solid Tumours at Mater Hospital, North SydneyRecruitment to open this month at Frankston Hospital, VictoriaFurther site to follow at Curie Oncology, SingaporeSYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- EnGeneIC Pty Ltd, a Sydney-based biotechnology company and leader in innovative cancer therapies, has announced the successful dosing of the first patient in its open-label, multicentre, Phase I/IIa clinical trial at Mater Hospital, Sydney. The trial (ENG19) is an essential next step in progressing EnGeneIC’s novel platform technology through the clinic and to market. It will assess the safety and efficacy of EGFR-targeted…

  • Medical Health Aged Care
  • 13/05/2025
  • 11:36
Dementia Australia

Templestowe show their support for people impacted by dementia

Templestowe community members turned up in force last weekend, showing their support for people impacted by dementia whilst getting active to improve their brain health. Participating in the 2025 Memory Walk & Jog at Westerfolds Park more than 290 people walked, ran and jogged to raise an impressive total of $30,000. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, raised funds, spread the word and donated. “There was an outstanding show of support from the Templestowe community who turned out in such large numbers for the first time in support of people impacted by dementia,”…

  • Contains:
  • Medical Health Aged Care
  • 13/05/2025
  • 11:16
Dementia Australia

South East Melbourne show their support for people impacted by dementia

South East Melbourne community members turned up in force last weekend, showing their support for people impacted by dementia whilst getting active to improve their brain health. Participating in the 2025 Memory Walk & Jog at Peter Scullin Reserve, Mordialloc, more than 325 people walked, ran and jogged to raise an impressive total of $40,000. Dementia Australia CEO Professor Tanya Buchanan extended her gratitude to all who participated, raised funds, spread the word and donated. “There was an outstanding show of support from the South East Melbourne community who turned out in such large numbers for the first time in…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.